They very well may be interchangeable. My reason is that ApresFlex (20% AKBA) was specifically shown to be better at 5-lipoxygenase inhibition then a similar Boswellin source (30% AKBA), and there’s some interesting early research into 5-LOX inhibition and prostate cancer. Always good to be cautious of cell studies of course.I always appreciate your input on things. This weekend, I'm going thru and finalize formula releases for Q4 of this year and Q1 of next year and compared your above to the prostate formula that I have designed. Some of it is the same and I have quite a few things included that aren't on your list.
For CardioAid, it is predominantly in an oil form so it would have to be softgel to go with one of the higher percentages; they do make a powder version but the percentages aren't as good and the price to use it is very high for what it is imo.
For ApresFlex, is there a particular reason you suggested this one as a Boswellin source? It is more commonly associated with joint health and regardless of use, I personally prefer Sabinsa's Super Boswellin. If you prefer pm's, I'd love to hear your reasoning if you do prefer ApresFlex or if you think of them as interchangeable.
Aflapin/ApresFlex vs 5-Loxin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974165/
Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon
Previous studies have shown that human prostate cancer cells constitutively generate 5-lipoxygenase (5-LOX) metabolites from arachidonic acid, and inhibition of 5-LOX blocks production of 5-LOX metabolites and triggers apoptosis in prostate cancer cells. ...
www.ncbi.nlm.nih.gov
Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis - Scientific Reports
Much of the morbidity and mortality due to prostate cancer happen because of castration-resistant prostate cancer (CRPC) which invariably develops after anti-androgenic therapy. FDA-approved enzalutamide is commonly prescribed for CRPC which works by blocking androgen receptor function. However...
www.nature.com
Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase
The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained exclusively by a rare group of cells possessed with stem cell properties. CSCs are characterized by features that include self-renewal, pluripotency and tumorigenicity, ...
www.ncbi.nlm.nih.gov